Related Experiment Video
Updated: May 8, 2026
Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
Published on: January 31, 2020
How nonhuman primate infant and mother-infant models can inform pediatric HIV-1 cure research
Claire-Maëlle Fovet1, Nabila Seddiki1,2
1Université Paris-Saclay, Inserm, CEA; Immune Diseases, Microbiology and Innovative Therapies (IDMIT/UMRS1184); Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Insights
Nonhuman primate models reveal critical insights into pediatric HIV-1 infection. Early treatment and novel immunotherapies show promise, but achieving sustained remission remains challenging.
Area of Science:
- Pediatric HIV-1 pathogenesis and immunology.
- Nonhuman primate (NHP) models for HIV-1 research.
Background:
- 1.4 million children worldwide live with HIV-1.
- Significant knowledge gaps exist in neonatal HIV-1 pathogenesis and curative strategies.
- NHP infant and mother-infant models are crucial for studying age-specific infection mechanisms and treatment responses.
Purpose of the Study:
- To investigate immune development in infants with HIV-1.
- To elucidate age-specific mechanisms of HIV-1 infection.
- To evaluate treatment responses in infant models.
Main Methods:
- Utilizing NHP infant and mother-infant models.
- Timed infections and longitudinal, multitissue sampling.
- Post-analytical treatment interruption (ATI) studies.
Main Results:
- Newborn macaques show accelerated HIV-1 progression with impaired interferon-I responses.
- Ultra-early antiretroviral treatment (ART) achieved temporary control post-ATI.
- Immunotherapies like CD4-mimetics and BCL-2 inhibitors reduced viral loads.
- Vaccines elicited superior antibody precursors in infants, but maternal antibody transfer was inefficient.
- AAV-delivered broadly neutralizing antibodies (bNAbs) provided multiyear protection.
Conclusions:
- NHP models dissect therapeutic windows for clinical translation.
- Advancing mother-infant NHP research is vital for pediatric ART-free remission strategies.
- Achieving sustained ART-free remission in pediatric HIV-1 remains a significant challenge.
Purpose Of Review:
An estimated 1.4 million children live with HIV-1, yet major gaps remain in understanding neonatal pathogenesis and curative strategies. Nonhuman primate (NHP) infant and mother-infant models provide a critical platform to investigate immune development, elucidate age-specific mechanisms of infection, and evaluate treatment responses, aspects that cannot be directly studied in humans.
Recent Findings:
Newborn macaques exhibit exaggerated gut and lymph nodes seeding, absent interferon-I responses, and accelerated progression compared to juveniles, while ultra-early antiretroviral treatment (ART, day 3) achieves 80% postanalytical treatment interruption (ATI) control that collapses by day 5 due to rapid reservoir fixation. Immunotherapies reveal mechanistic constraints: interleukin-15 agonists paradoxically prolong infected cell survival, whereas CD4-mimetics and BCL-2 inhibitors reduce proviral loads. Germline-targeting SOSIP vaccines elicit superior broadly neutralizing antibodies (bNAb) precursors in infants versus adults, though maternal antibody transfer remains inefficient. Neonatal AAV-delivered bNAbs exploit immune tolerance to confer multiyear protection against SHIV challenges.
Summary:
NHP models, via timed infections, longitudinal and multitissue sampling, and safe ATI, dissect therapeutic windows guiding clinical translation. Advancing mother-infant NHP research is therefore essential to support the development of pediatric strategies for ART-free remission, a goal that remains challenging to achieve.
